Historical AI Consensus
This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.
- Symbol
- NTRA.NASDAQ
- Batch
- 7
- Published
- September 20, 2026
- AI Advisors
- 14
Historical AI Consensus Investment Thesis
Natera (NTRA) Stock Forecast and AI Rating
Forecast targets and rating
Published batch rating
PARTIAL SELL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
SELL ALL$323
-12.6%5-Year
PARTIAL SELL$362
-2.1%Published batch insight
Clinical Monopoly Encounters Valuation Gravity Amid Elevating Cost Of Capital
A sharp divergence defines the outlook: high consensus affirms Signatera's rapid clinical adoption and expanding gross margins, yet deep disagreement surrounds valuation durability. At twenty times sales in a high-rate regime, multiple contraction threatens to neutralize volume growth unless genuine operating profitability materializes.
This analysis preserves the original published batch. Audit published forecasts in full transparency
Universal Investor (Polymath), Sherlock Holmes (Whistleblower), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Elon Musk (Visionary), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTFull published thesis
Executive Summary
If you invested $10,000 in Natera at the forecast anchor (2026-09-18): $9,789 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 346.91 | -6.09% | -6.09% | Persistent 5% Treasury yields induce multiple compression across high-valuation diagnostics, dampening equity performance despite robust Q3 Signatera test volumes and solid operational execution. |
| Q1 2027 | 332.01 | -4.30% | -10.12% | Full-year 2026 disclosures confirm top-line growth near $2.9 billion, but continuing GAAP operating deficits and heavy 2027 R&D budgets prompt institutional multiple adjustments. |
| Q2 2027 | 338.43 | +1.93% | -8.38% | Expanded Medicare MolDX indications in oncology surveillance lift realized average selling prices, sparking a tactical relief rally supported by gross margins holding above 65%. |
| Q3 2027 | 322.92 | -4.58% | -12.58% | Private commercial health insurers intensify prior-authorization friction across molecular panels, slowing sequential cash collections and reigniting multiple compression across high-beta medical technology. |
| Q4 2027 | 327.63 | +1.46% | -11.30% | Encouraging early cancer detection cohort readouts and expanded guideline inclusion in breast cancer provide sentiment support, offsetting tax-loss selling into year-end. |
| Q1 2028 | 321.58 | -1.85% | -12.94% | Initial 2028 guidance indicates research spending growth is beginning to moderate relative to sales, though elevated cost-of-capital hurdles keep valuation multiples restrained. |
| Q2 2028 | 325.50 | +1.22% | -11.88% | Laboratory sequencing automation and rising test density lower per-sample costs, lifting unit contribution margins and driving positive operational cash flow expansion. |
| Q3 2028 | 326.92 | +0.44% | -11.50% | International commercialization in Japan under PMDA reimbursement provides geographic diversification, helping balance competitive pricing noise from rival tumor-naive assay launches. |
| Q4 2028 | 325.30 | -0.50% | -11.93% | Resolution of outstanding false-advertising litigation liabilities and diagnostic fee schedule reviews introduces brief headline drag, followed by fundamental balance-sheet stabilization. |
| Q1 2029 | 329.73 | +1.36% | -10.74% | Fiscal 2028 filings demonstrate the first sustained approach to GAAP operating breakeven, broadening institutional interest among quality-oriented healthcare funds. |
| Q2 2029 | 335.39 | +1.71% | -9.21% | Updated pan-cancer guideline endorsements expand the addressable surveillance cohort, generating steady sequential accession growth and reinforcing Signatera's clinical standard-of-care moat. |
| Q3 2029 | 334.94 | -0.13% | -9.33% | Commercial payer contract renewals enforce modest pricing concessions on serial testing, keeping forward price-to-sales multiples anchored to mature diagnostic industry baselines. |
| Q4 2029 | 340.20 | +1.57% | -7.90% | Biopharmaceutical companion diagnostic partnerships deliver milestone and royalty payments, strengthening working capital and supporting share valuation through year-end. |
| Q1 2030 | 340.85 | +0.19% | -7.73% | Annual revenue crosses $4.8 billion with verifiable GAAP profitability, marking the formal corporate transition from speculative growth asset to mature medical utility. |
| Q2 2030 | 345.43 | +1.34% | -6.49% | Expanding commercial coverage across community oncology practices drives test volume scale, while higher throughput cushions against lingering industry reimbursement scrutiny. |
| Q3 2030 | 346.02 | +0.17% | -6.33% | Rival next-generation liquid biopsy platforms intensify competitive bidding for hospital laboratory contracts, producing moderate pricing headwinds that check multiple expansion. |
| Q4 2030 | 350.77 | +1.37% | -5.04% | Sustained annual free cash flow exceeding $400 million provides strategic flexibility, enabling potential share buybacks to mitigate executive stock-based compensation dilution. |
| Q1 2031 | 353.61 | +0.81% | -4.27% | Consolidated 2030 results confirm durable double-digit top-line compounding and solid margins, establishing a stable fundamental foundation for the equity. |
| Q2 2031 | 359.70 | +1.72% | -2.62% | Maturing domestic oncology surveillance is augmented by expanding international diagnostic demand, maintaining steady cash generation across diversified disease indications. |
| Q3 2031 | 361.59 | +0.52% | -2.11% | The five-year scenario concludes with the enterprise fully transitioned into a profitable diagnostics compounder, where robust operational growth has absorbed multiple normalization. |
The base-case economic thesis centers on an acute divergence between operational compounding and equity duration sensitivity. Clinically, Signatera is solidifying standard-of-care status in oncology molecular residual disease, where longitudinal surveillance protocols convert episodic tests into high-visibility recurring volume. Combined with reproductive screening cash flows and sequencing automation, enterprise revenue is set to scale from $2.71 billion toward $6.0 billion by 2031 with gross margins above 65%. However, equity pricing at nearly twenty times revenue in a 5% sovereign yield environment discounts flawless execution while ignoring structural capital costs. Trailing free cash flow of $71.7 million against a $53 billion market capitalization reflects heavy reliance on stock-based compensation add-backs. As top-line growth decelerates toward 20%, multiple compression toward high single-digit sales multiples will absorb operational gains, leaving equity returns modest.
Key insights
- Longitudinal surveillance transforms diagnostic testing into a recurring subscription-like revenue engine, yet realized ASP expansion faces intensifying resistance from private commercial payers.
- Intangible research commitments exceeding $800 million annually build defensible clinical evidence moats but defer statutory GAAP net earnings well into late 2028.
- Dilution from equity incentives and contingent legal liabilities from false-advertising verdicts reduce the per-share economic value captured by public equity holders.
Natera is expanding rapidly as doctors increasingly rely on its Signatera test to detect cancer recurrence early. This clinical success and steady prenatal testing are driving strong sales growth and wider gross profit margins. However, the stock price already reflects immense future optimism, trading at twenty times annual revenue while the company still posts accounting losses and interest rates remain high.
Key insights
- Patients receive repeat testing over many years, creating steady recurring revenue for laboratories.
- Enormous spending on clinical trials proves the test works, but delays true company profits.
- Expensive stock grants and legal disputes slowly dilute the shares owned by everyday investors.
Deep Dive
Prevailing market consensus treats Signatera as an unassailable clinical monopoly destined to capture the multi-billion-dollar oncology surveillance market. Sell-side research extrapolates 35% compound revenue expansion and eventual 70% gross margins into perpetuity. Anchored by recent NCCN guideline milestones, the crowd prices secular dominance while blithely dismissing persistent GAAP losses, commercial insurer prior-authorization friction, and extreme valuation multiples in a 5% Treasury yield regime.